However, the relationship was less strong in the PARAGON-HF trial [63] in HFpEF patients, which showed a considerable effect of SGLT2i on the reduction of NT-proBNP but a moderate effect on the primary outcome in the subgroups of men and patients with higher LVEF. The gene discussed is NPPB; the disease is hydrops fetalis.